LifeVantage Corporation reports developments for a health and wellness company built around nutrigenomics, dietary supplements, skin and hair care products, nootropic energy drink mixes, and pet supplements. Its product line includes Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84, AXIO, TrueScience skin and hair care products, and Petandim, sold through independent Consultants to customers.
Company news commonly covers quarterly results, regional sales trends, product innovation, patents tied to cellular-signaling supplement compositions, consultant events and training, international market expansion, executive leadership changes, share repurchases, and cash dividends. Updates also describe capital allocation and the company’s direct-selling business model.
LifeVantage Corporation (Nasdaq: LFVN) reported record fiscal 2020 revenue of $233 million, marking a 3.1% increase year-over-year. The fourth quarter alone generated $59.4 million in revenue, a 5.7% increase from the previous year. Adjusted EBITDA rose 31.3% to $24 million. The company ended the fiscal year with strong cash flow, holding $22.1 million in cash and zero debt. Earnings per share for fiscal 2020 were $0.79, up from $0.50 in fiscal 2019. Looking ahead, the company expects $240 million to $251 million in revenue for fiscal 2021.
LifeVantage Corporation (Nasdaq: LFVN) reported third-quarter fiscal 2020 revenue of $56.1 million, a slight increase from the previous year. Adjusted EBITDA rose 26.4% to $5.1 million. Revenue in the Americas declined 0.5%, while Asia/Pacific & Europe saw a 1.6% increase. Total active accounts decreased 3.8% sequentially. Q3 earnings per diluted share were $0.11, compared to $0.12 last year. The company reiterated adjusted EPS guidance of $0.74 to $0.79 for fiscal 2020, anticipating revenue will fall below earlier estimates due to the pandemic.